Close Menu


News and reporting on melanoma.

The Phase III trial evaluated tebentafusp in patients with HLA-A*02:01-positive metastatic uveal melanoma compared to Keytruda, Yervoy, or chemo.

The personalized neoantigen-based vaccine, manufactured on a per-patient basis, will be evaluated in combination with Keytruda for melanoma and NSCLC.  

The FDA also granted tebentafusp breakthrough therapy designation to treat patients with metastatic uveal melanoma.

Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes.

The proof-of-principle study demonstrated the feasibility of altering the microbiome to elicit anti-PD-1 response and shed light on which patients might benefit.

Treating patients with their own lymphocytes has been tricky to define as a product from the commercial perspective, but a forthcoming approval may change that.  

Based on the safety and anti-tumor activity seen among patients receiving Achilles' clonal neoantigen-targeting T cells, the trials will continue as planned.

The TuPro study will evaluate whether a comprehensive suite of routine and emerging tests can add value to treatment decision making and improve outcomes.  

OncoHost will use the funding to finance clinical trials, open a US location, and prepare to launch its proteomics platform called Prophet.

Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.